Ziv-aflibercept use in metastatic colorectal cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Molecular Survival Strategies Against Kidney Filtration: Implications for Therapeutic Protein Engineering.Biophysica · 2026
   Article
2. Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.Heliyon · 2024
   Review
3. Antibody-Loaded Nanoplatforms for Colorectal Cancer Diagnosis and Treatment: An Update.Pharmaceutics · 2023
   Review
4. Osteonecrosis of the jaw associated with ziv-aflibercept.Journal of gastrointestinal oncology · 2016
   Article
5. Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC).Targeted oncology · 2016
   Review
6. Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer.Technology in cancer research & treatment
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.